

PIONEERING TARGETED PROTEIN DEGRADATION

 **KYMER A**

RAISED **\$450M** IN 2020 DEALS
& FINANCINGS

Priced an over-subscribed, upsized, & above the range IPO in August, supported by blue-chip public biotech investors

Partnered with Sanofi in July to advance multiple protein degrader therapies, while preserving access to US market

NASDAQ : **KYMR**

...

[LEARN MORE](#)

